ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.
LowReport
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
LowReport
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
LowReport
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. [Yahoo! Finance]
MediumReport
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: